CNSX:CMND.CN

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on:

Tuesday, February 27, 2024

Therapy, Central nervous system, TEL, Obesity, Ketamine, Patent, Ibogaine, PCT, Patent Cooperation Treaty, MDMA, PEA, CWY, Disorder, DSM-IV codes, Pharmaceutical industry

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points:

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
In addition, seven applications were filed under the PCT.

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Retrieved on:

Tuesday, February 20, 2024

Therapy, Central nervous system, DMT, LSD, TEL, Patent, Patent Cooperation Treaty, Psilocybin, PEA, CWY, Disorder, Lysergic acid diethylamide

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points:

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.
These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
"We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc’s Chief Executive Officer, Oz Adler.
"We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

Retrieved on:

Thursday, January 4, 2024

TEL, Psilocybin, Patent, CWY, MDMA, LSD, Lysergic acid diethylamide, IP, PEA, Central nervous system, Patient, Safety, Therapy, Disorder, DMT, Pharmaceutical industry

TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reflects on the successful collaboration in 2023 with Clearmind Medicine Inc. (“Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.

Key Points:

Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.
The patent applications are for novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA) and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, Ketamine, and PEA.
PEA is the active ingredient of SciSparc’s proprietary CannAmide™.
As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Retrieved on:

Tuesday, August 1, 2023

The provisional patent application was filed with the United States Patent and Trademark Office.

Key Points:

The provisional patent application was filed with the United States Patent and Trademark Office.
This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.
This patent prospect corresponds well with SciSparc’s robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

Retrieved on:

Friday, June 16, 2023

Tel Aviv, Israel, June 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of the Company's ongoing collaboration with Clearmind Medicine Inc. (NASDAQ, CSE: CMND) ("Clearmind"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, a research agreement with the Hebrew University of Jerusalem was signed, to evaluate SciSparc's and Clearmind's proprietary combination treatment for obesity and metabolic syndrome.

Key Points:

"We are excited to continue our fruitful journey of scientific discovery alongside Clearmind Medicine and the esteemed Professor Joseph Tam of the Hebrew University of Jerusalem," stated Oz Adler, Chief Executive Officer of SciSparc.
"We believe that the synergistic effect of our proprietary CannAmide™ and Clearmind's proprietary MEAI has immense potential in treating obesity and metabolic syndrome, two global health challenges of significant scale.
Additionally, the treatment yielded a normalization of insulin levels, improved glucose tolerance, and reduced fat and triglyceride accumulation in the liver.
Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

Retrieved on:

Friday, April 21, 2023

TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).

Key Points:

TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).
The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide (“PEA”) for the treatment of depression.
Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders.
An additional six patent applications have been filed for the combination of SciSparc's PEA and lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), 3,4 methylenedioxymethamphetamine (MDMA), ibogaine and ketamine.

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

Retrieved on:

Wednesday, February 22, 2023

Central nervous system, FSE, CSE, DSM-IV codes, CWY, Patent, Lysergic acid diethylamide, N, Psilocybin, Therapy, United States Patent and Trademark Office, Obesity, Pharmaceutical industry

Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psychedelic-based compounds.

Key Points:

Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psychedelic-based compounds.
Overall, as part of this collaboration, six other patent applications have been filed by Clearmind with the USPTO for various combinations, three of them for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders, and recently for novel proprietary combinations of lysergic acid diethylamide (“LSD”), psilocybin, and N,N-dimethyltryptamine (“DMT”) and SciSparc’s PEA, the active ingredient of its proprietary CannAmide™.
As part of the collaboration agreement, any assets generated from the collaboration will belong to both companies.

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

Retrieved on:

Wednesday, February 15, 2023

TEL, Patent, PEA, Lysergic acid diethylamide, CWY, Therapy, United States Patent and Trademark Office, Safety, Obesity, Psilocybin, FSE, Central nervous system, DSM-IV codes, CSE, Pharmaceutical industry

TEL AVIV, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, three provisional patent applications were filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).

Key Points:

The patent applications refer to novel proprietary combinations of lysergic acid diethylamide (“LSD”), psilocybin, and N,N-dimethyltryptamine (“DMT”) and SciSparc’s Palmitoylethanolamide (“PEA”), the active ingredient of its proprietary CannAmide™.
Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders.
“These new patent applications continue to support our findings of the major role CannAmideTM, our proprietary PEA formulation, plays in SciSparc’s various proprietary combination treatments,” said Oz Adler, Chief Executive Officer of SciSparc.
“All our clinical and pre-clinical studies performed to date, in numerous diseases and conditions, indicated CannAmide™ ability to reduce doses while maintaining therapeutic efficacy and while increasing safety.

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

Retrieved on:

Thursday, September 22, 2022

"Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind's.

Key Points:

"Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind's.
"We believe that combining MEAI with SciSparc's CannAmide may create a great opportunity in treating these conditions."
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
For example, SciSparc is using forward-looking statements when it discusses the ability of the combination of MEAI with SciSparc's CannAmide to successfully treat obesity and metabolic conditions.

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Retrieved on:

Wednesday, August 24, 2022

TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).

Key Points:

"We are excited about these recent results in light of the potential synergistic effect between SciSparcs CannAmide and Clearminds MEAI, as previously demonstrated.
These results continue to indicate that we may have a targeted treatment for cocaine addiction within our reach, commented Oz Adler, SciSparc's Chief Executive Officer.
"These results reinforce our decision to enter a collaboration between the two companies."
Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University.